A Surview of Recent Patents on Anti-Infective Therapy for Clostridium difficile

ISSN: 2212-4071 (Online)
ISSN: 1574-891X (Print)

Volume 12, 2 Issues, 2017

Download PDF Flyer

Recent Patents on Anti-Infective Drug Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Dieter Kabelitz
Institute of Immunology
Universitätsklinikum Schleswig-Holstein
Campus Kiel
Arnold-Heller-Straße 3
Kiel, D-24105

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

A Surview of Recent Patents on Anti-Infective Therapy for Clostridium difficile

Recent Patents on Anti-Infective Drug Discovery, 8(2): 139-149.

Author(s): Germine S. Soliman, Bechoi Saleib and Stephen J Scholand.

Affiliation: St. Mary’s Hospital Department of Internal Medicine, 56 Franklin Street, Waterbury, CT 06706 (203) 709-6000, USA.


Clostridium difficile has become the most common infectious cause of healthcare-associated diarrhea, with serious morbidity, prolonged hospitalization and even death. Treatment of the disease utilizing today’s therapies does not guarantee a successful outcome. In the past decade, many new ideas and inventions have surfaced exploring different treatment strategies of Clostridium difficile associated diarrhea (CDAD). These treatments include antitoxins, novel antimicrobials, immunoglobulins and large inert synthetic compounds. In this paper, we survey of a number of representative patents issued from 2000 to the present targeting treatment of this difficult and dreaded disease.


Bacterial toxin, Clostridium difficile, drug target, patents.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 2
First Page: 139
Last Page: 149
Page Count: 11
DOI: 10.2174/1574891X113089990016
Price: $100

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science